Interleukin-1 (IL-1) is a proinflammatory cytokine and IL-1 receptor antagonist (IL-1ra) is a natural inhibitor that binds to IL-1 receptor type I without inducing signal transduction. It is ...

The Interleukin-1 Receptor-Like 2 (IL-1RL2) cytokine can promote inflammatory diseases and have a role in controlling infection. Skip to content. Menu. Medical Home Life Sciences Home.

The Role of the Interleukin-1–Receptor Antagonist in Blocking Inflammation Mediated by Interleukin-1. Author: Charles A. Dinarello, M.D. Author Info & Affiliations. Published September 7, 2000.

Plasma levels of interleukin-1 receptor antagonist correlated with cerebrospinal fluid neurofilament light levels and predicted disability among patients with MS, according to a study presented at ...

Genascence’s GNSC-001 for knee osteoarthritis receives US FDA regenerative medicine advanced therapy designation: Palo Alto, California Saturday, July 19, 2025, 16:30 Hrs [IST] ...

The Interleukin-1 Receptor-Like 2 (IL-1RL2) cytokine can promote inflammatory diseases and have a role in controlling infection. The receptor can recognize multiple agonists and has been ...

A multicenter, double-blind, dose ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression ...

Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 ...

Scientists at Indiana University School of Medicine have identified a new approach that could transform treatment for acute ...

Deficiency of interleukin-1 (IL-1) receptor antagonist (DIRA) is an autosomal recessive monogenic autoinflammatory disease caused by a genetic mutation in the IL1RN gene, ...

This resulted in a hazard ratio of 1.61 (95% CI, 1.25 to 2.08), yielding a more than 99.9% posterior probability of superiority of the interleukin-6 receptor antagonists to control.